<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990834</url>
  </required_header>
  <id_info>
    <org_study_id>MCAST</org_study_id>
    <nct_id>NCT00990834</nct_id>
  </id_info>
  <brief_title>Muscle Characteristics Associated With Statin Therapy</brief_title>
  <official_title>Muscle Characteristics Associated With Statin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scripps Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the mechanism of statin-related myopathy by
      evaluating muscle samples before and after statin exposure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Statins have been proven to reduce cardiovascular events and mortality in large clinical
      trials but remain underutilized partly due to the associated myopathy. Severe reactions
      manifested as rhabdomyolysis are rare but myalgia is commonly noted in clinical practice. The
      pathophysiology of these events remains obscure. Previous studies suggest that statins block
      the downstream products (such as cellular signaling molecules) of the mevalonate pathway
      needed for normal muscle function. Other studies show that statins are associated with gene
      expressions involved in muscle damage such as atrogin-1. We will quantify these entities pre
      and post statin therapy to better understand these reactions.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to recruit subjects.
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrogin-1 expression.</measure>
    <time_frame>One to eight months.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intramuscular Ras level.</measure>
    <time_frame>One to eight months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intramuscular Coenzyme Q10 level.</measure>
    <time_frame>One to eight months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intramuscular mitochondrial to nuclear DNA ratio.</measure>
    <time_frame>One to eight months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intramuscular geranylgeranylpyrophosphate.</measure>
    <time_frame>One to eight months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPAR-gamma coactivator-1-alpha expression.</measure>
    <time_frame>One to eight months.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hydroxymethylglutaryl-CoA Reductase Inhibitors</condition>
  <condition>Myopathy</condition>
  <arm_group>
    <arm_group_label>Statin exposure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects' endpoints will be measured before and after one to eight months of statin exposure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>simvastatin 80 mg PO daily for one to eight months.</description>
    <arm_group_label>Statin exposure</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary surgeon's permission.

          -  Patient is &gt; 21 years of age.

          -  Patient will go through a two phase surgery with the two procedures one to eight
             months apart.

          -  Patient or representative understands the nature of the study.

          -  Normal thyroid stimulating hormone (TSH).

          -  LDL-cholesterol &gt; 100 mg/dL or highly sensitive C-reactive protein (hsCRP) &gt; 2.0.

          -  One of the following risk factors: male &gt; 45 year old or female &gt; 55 year old, smoker,
             hypertension, first degree family history of coronary artery disease &lt; 55 year old,
             HDL &lt;40 mg/dL, chronic kidney disease, diabetes mellitus, previous TIA or stroke,
             previous coronary artery disease.

        Exclusion Criteria:

          -  Has been on a lipid-lowering medication previously.

          -  Severe illness (e.g. trauma or sepsis) more than 24 hours before obtaining the first
             biopsy.

          -  Less than a 10% reduction of LDL after 3 months of therapy (indicative of
             non-adherence).

          -  Contraindications to statins such as liver failure.

          -  History of underlying muscle disorder.

          -  Taking amiodarone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tam H Truong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul S Phillips, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps-Mercy Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301-7.</citation>
    <PMID>7566020</PMID>
  </reference>
  <reference>
    <citation>Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998 Nov 5;339(19):1349-57.</citation>
    <PMID>9841303</PMID>
  </reference>
  <reference>
    <citation>Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006 Dec 19;114(25):2788-97. Epub 2006 Dec 11. Review.</citation>
    <PMID>17159064</PMID>
  </reference>
  <reference>
    <citation>Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14.</citation>
    <PMID>16453090</PMID>
  </reference>
  <reference>
    <citation>Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol. 1997 Jul;145(1):91-8.</citation>
    <PMID>9221828</PMID>
  </reference>
  <reference>
    <citation>Nishimoto T, Ishikawa E, Anayama H, Hamajyo H, Nagai H, Hirakata M, Tozawa R. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicol Appl Pharmacol. 2007 Aug 15;223(1):39-45. Epub 2007 May 24.</citation>
    <PMID>17599378</PMID>
  </reference>
  <reference>
    <citation>Matzno S, Yasuda S, Juman S, Yamamoto Y, Nagareya-Ishida N, Tazuya-Murayama K, Nakabayashi T, Matsuyama K. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J Pharm Pharmacol. 2005 Nov;57(11):1475-84.</citation>
    <PMID>16259781</PMID>
  </reference>
  <reference>
    <citation>Young JM, Florkowski CM, Molyneux SL, McEwan RG, Frampton CM, George PM, Scott RS. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol. 2007 Nov 1;100(9):1400-3. Epub 2007 Aug 16.</citation>
    <PMID>17950797</PMID>
  </reference>
  <reference>
    <citation>Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, Babiychuk EB. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006 Sep;210(1):94-102.</citation>
    <PMID>16799920</PMID>
  </reference>
  <reference>
    <citation>Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13;110(2):227-39. Review. Erratum in: Circulation. 2004 Aug 10;110(6):763.</citation>
    <PMID>15249516</PMID>
  </reference>
  <reference>
    <citation>Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149-58.</citation>
    <PMID>12686036</PMID>
  </reference>
  <reference>
    <citation>Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006 Mar 23;354(12):1264-72.</citation>
    <PMID>16554528</PMID>
  </reference>
  <reference>
    <citation>Hanai J, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP, Lecker SH. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest. 2007 Dec;117(12):3940-51.</citation>
    <PMID>17992259</PMID>
  </reference>
  <reference>
    <citation>Shishehbor MH, Patel T, Bhatt DL. Using statins to treat inflammation in acute coronary syndromes: Are we there yet? Cleve Clin J Med. 2006 Aug;73(8):760-6. Review.</citation>
    <PMID>16913201</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>May 21, 2015</last_update_submitted>
  <last_update_submitted_qc>May 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <name_title>Truong, H. Tam, MD</name_title>
    <organization>Scripps Mercy Hospital</organization>
  </responsible_party>
  <keyword>Statin</keyword>
  <keyword>Myopathy</keyword>
  <keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
  <keyword>Atrogin-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

